Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Iota-carrageenan  COVID-19 treatment studies for Iota-carragee..  C19 studies: Iota-carragee..  Iota-carragee..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2
Morokutti-Kurz et al., International Journal of General Medicine, doi:10.2147/IJGM.S325861, NCT04533906 (history)
Morokutti-Kurz et al., The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication.., International Journal of General Medicine, doi:10.2147/IJGM.S325861, NCT04533906
Sep 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 31 subjects analyzing iota-carrageenan concentration in saliva after using an iota-carrageenan containing lozenge, showing sufficient concentration to neutralize common respiratory viruses including SARS-CoV-2. For SARS-CoV-2, the IC90 was exceeded by 121-fold (p < 0.001). NCT04533906 (history).
Morokutti-Kurz et al., 7 Sep 2021, peer-reviewed, 12 authors, trial NCT04533906 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperIota-carragee..All
Abstract: International Journal of General Medicine Dovepress open access to scientific and medical research International Journal of General Medicine For personal use only. Open Access Full Text Article C L I N I C A L T R I A L R E P O RT The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2 Martina Morokutti-Kurz 1 Nicole Unger-Manhart 1 Philipp Graf 1 Pia Rauch 2 Julia Kodnar 1 Maximilian Große 2 Christian Setz 2 Markus Savli 3 Friedrich Ehrenreich 4 Andreas Grassauer 1 Eva Prieschl-Grassauer 1 Ulrich Schubert 2 1 Marinomed Biotech AG, Korneuburg, 2100, Austria; 2Institute of Virology, Friedrich-Alexander University ErlangenNürnberg (FAU), Erlangen, Germany; 3 Biostatistik & Consulting Savli, Hartberg, 8230, Austria; 4Practice Dr. Friedrich Ehrenreich, Vienna, 1170, Austria Correspondence: Martina MorokuttiKurz Marinomed Biotech AG, Korneuburg, 2100, Austria Email martina.morokuttikurz@marinomed.com Ulrich Schubert Institute of Virology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany Email ulrich.schubert@fau.de Purpose: The aim of this study was to investigate whether sucking of an iota-carrageenan containing lozenge releases sufficient iota-carrageenan into the saliva of healthy subjects to neutralize representatives of the most common respiratory virus families causing common cold and SARS-CoV-2. Patients and Methods: In this monocentric, open label, prospective clinical trial, 31 healthy subjects were included to suck a commercially available iota-carrageenan containing lozenge. Saliva samples from 27 subjects were used for ex vivo efficacy analysis. The study’s primary objective was to assess if the mean iota-carrageenan concentration of the saliva samples exceeded 5 µg/mL, which is the concentration known to reduce replication of human rhinovirus (hRV) 1a and 8 by 90%. The iota-carrageenan concentration of the saliva samples was analyzed by UV-Vis spectroscopy. The antiviral effectiveness of the individual saliva samples was determined in vitro against a panel of respiratory viruses including hRV1a, hRV8, human coronavirus OC43, influenza virus A H1N1pdm09, coxsackievirus A10, parainfluenza virus 3 and SARS-CoV-2 using standard virological assays. Results: The mean iota-carrageenan concentration detected in the saliva exceeds the concentra­ tion needed to inhibit 90% of hRV1a and hRV8 replication by 134-fold (95% CI 116.3–160.8-fold; p < 0.001). Thus, the study met the primary endpoint. Furthermore, the iota-carrageenan saliva concentration was 60 to 30,351-fold higher than needed to reduce viral replication/binding of all tested viruses by at least 90% (p < 0.001). The effect was most pronounced in hCoV OC43; in case of SARS-CoV-2, the IC90 was exceeded by 121-fold (p < 0.001). Conclusion: Sucking an iota-carrageenan containing lozenge releases sufficient iota-carra­ geenan to neutralize and inactivate the most abundant respiratory viruses as well as pandemic SARS-CoV-2. The lozenges are therefore an appropriate measure to reduce the viral load at the site of infection, hereby presumably limiting transmission within a population as well as translocation to the lower respiratory tract. Trial Registration: NCT04533906. Keywords: iota-carrageenan, respiratory viruses, corona virus, lozenges, antiviral, clinical study,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit